The Evidence Pack: How a Novel RNA Drug Became the First to Reduce Pancreatitis Risk in Severe Hypertriglyceridemia

For millions of people, nutrition and lifestyle modifications are the first line of defense against metabolic disease. But when fasting triglyceride levels cross the 500 mg/dL threshold—entering the territory of severe hypertriglyceridemia—diet alone is rarely enough. At these extreme concentrations, the blood can become visibly milky with fat, and the risk of acute pancreatitis, a sudden and potentially life-threatening inflammation of the pancreas, skyrockets.[1]

Historically, physicians have relied on a combination of strict low-fat diets, fibrates, and high-dose omega-3 fatty acids to manage the condition. Yet, these traditional interventions often fall short for patients with severe genetic or metabolic drivers. More critically, while older medications could lower triglyceride numbers on a lab report, none had ever generated enough clinical trial data to prove they actually prevented real-world pancreatitis attacks.[1]

That paradigm shifted on June 24, 2026, when the U.S. Food and Drug Administration (FDA) approved olezarsen, marketed as Tryngolza. Developed by Ionis Pharmaceuticals, the monthly injection became the first and only therapy proven to reduce both circulating triglycerides and the incidence of acute pancreatitis in adults with severe hypertriglyceridemia.

The breakthrough stems from a pivot away from broad metabolic interventions toward precision genetic targeting. Olezarsen belongs to a class of drugs known as antisense oligonucleotides (ASOs). Rather than attempting to clear fat from the blood directly, the drug intercepts the genetic instructions that regulate how the body processes that fat.[1][2]

To understand how it works, one must look at the liver. The liver produces a protein called apolipoprotein C-III (APOC3), which acts as a molecular brake on lipid metabolism. Specifically, APOC3 inhibits lipoprotein lipase (LPL), the primary enzyme responsible for breaking down triglyceride-rich lipoproteins in the bloodstream.[1][2]

In patients with severe hypertriglyceridemia, this braking mechanism is often overactive, causing dangerous fats to accumulate. Olezarsen is a synthetic strand of nucleic acids designed to perfectly match the messenger RNA (mRNA) that carries the blueprint for APOC3.[1][2]

When olezarsen binds to the APOC3 mRNA in the liver, it triggers an enzyme called RNase H1 to cleave and destroy the genetic message. Without the mRNA blueprint, the liver stops producing the APOC3 protein. With the molecular brake removed, the body's natural lipid-clearing machinery accelerates, rapidly sweeping triglycerides out of the blood.[1][2]

A crucial design feature of olezarsen is its delivery system. The drug is conjugated with N-acetylgalactosamine (GalNAc), a specialized sugar molecule. Liver cells have abundant receptors that specifically bind to GalNAc, meaning the drug is pulled almost exclusively into the liver where it is needed, minimizing systemic exposure and allowing for a low, once-monthly subcutaneous dose.[1]

The clinical evidence supporting the FDA's decision rests primarily on two massive Phase 3 trials: CORE-TIMI 72a and CORE2-TIMI 72b. Together, the studies enrolled 1,061 adults with severe hypertriglyceridemia. The participants entered the trials with a staggering average baseline triglyceride level of 1,116 mg/dL—more than seven times the normal upper limit.[2][3]

The results were definitive. At the six-month mark, patients receiving the 80 mg dose of olezarsen experienced a placebo-adjusted reduction in fasting triglycerides of up to 72%. Furthermore, 86% of the treated patients successfully lowered their triglyceride levels below the critical 500 mg/dL danger threshold, sustaining those reductions through a full year of treatment.

But the most vital finding was the clinical outcome. In a pooled analysis of the trials, olezarsen reduced the rate of acute pancreatitis events by 85% compared to the placebo group. For patients with the highest baseline triglycerides and a prior history of pancreatitis, treating just four individuals for one year was enough to prevent one acute attack.[2]

This achievement bridges a long-standing gap in lipidology. For decades, researchers struggled to prove that lowering triglycerides directly translated to fewer hospitalizations for pancreatic inflammation. Olezarsen provided the definitive evidence that targeted APOC3 inhibition alters the actual clinical course of the disease.[1][2]

The safety profile of the new RNA therapy also represents a significant step forward. First-generation ASO drugs targeting lipid pathways occasionally caused severe thrombocytopenia, a dangerous drop in blood platelets. Thanks to the highly targeted GalNAc delivery system, olezarsen avoided these systemic issues. The most common adverse reactions reported in the trials were mild injection-site reactions and occasional, manageable elevations in liver enzymes.[1][2]

While the current approval focuses specifically on severe hypertriglyceridemia and pancreatitis risk, the implications of APOC3 inhibition extend further. Elevated triglycerides are increasingly recognized as a major driver of residual cardiovascular risk—the heart attacks and strokes that occur even when a patient's LDL 'bad' cholesterol is controlled by statins.[1]

Ongoing research, including the ESSENCE-TIMI 73b trial, is investigating olezarsen's efficacy in a broader population of patients with moderate hypertriglyceridemia and established cardiovascular disease. Early data suggests the drug can normalize triglycerides in over 80% of these patients, potentially offering a new tool to combat atherosclerosis.

For now, the approval of olezarsen marks a profound shift in how medicine approaches severe metabolic disorders. By utilizing RNA technology to rewrite the body's lipid-clearing instructions, science has provided a definitive answer to a condition that once defied treatment. For patients who have lived in constant fear of the next sudden, agonizing pancreatic attack, it represents a tangible restoration of safety and metabolic control.[1]